EFNA2 and Alzheimer disease: Even though the comparison of NPC markers did not reveal any neuroectodermal acquisition defects as previously described in HD and AD NPCs [16,29,30,31], the transcriptome profile of mutant NPCs indicates differences in 32 factors (26 upregulated and 6 downregulated) (Figure 2B, Supplementary Table S5) including the neurogenic molecules, NeuroD1, NeuroG1, NeuroG2, EDN1, CHRDL1, ERBB3, EFNA2, SOX8, LGI4, NTRK1, ISLR2, FOXD3, DCDC2, FOXN4, and NTN5.